Table 1 Patients’ characteristics, stratified by DPP4a tertiles
From: Prognostic value of plasma DPP4 activity in ST-elevation myocardial infarction
| Â | Total | T1 | T2 | T3 | p value |
|---|---|---|---|---|---|
U/L |  | <23.45 | 23.45–31.30 | >31.30 |  |
N | 625 | 207 | 210 | 208 | – |
Age (years) | 57.4 ± 11.4 | 58.1 ± 11.7 | 58.2 ± 11.5 | 55.8 ± 11.0 | 0.049 |
Male, n (%) | 519 (81.9) | 174 (84.1) | 172 (81.9) | 173 (83.2) | 0.35 |
BMI | 25.8 ± 3.4 | 25.8 ± 3.6 | 25.7 ± 3.3 | 26.0 ± 3.3 | 0.61 |
Hypertension, n (%) | 306 (50.9) | 117 (56.3) | 103 (49.0) | 86 (41.3) | 0.01 |
Type 2 diabetes, n (%) | 149 (23.8) | 58 (28.0) | 49 (23.3) | 42 (20.2) | 0.17 |
Current smoker, n (%) | 282 (45.1) | 80 (38.6) | 94 (44.7) | 108 (51.9) | 0.03 |
Ex-smoker, n (%) | 75 (12.0) | 31 (15.0) | 25 (11.9) | 19 (9.1) | 0.19 |
Previous MI, n (%) | 77 (12.3) | 23 (11.1) | 23 (11.0) | 31 (14.9) | 0.39 |
Anterior MI, n (%) | 322 (51.5) | 111 (53.6) | 110 (52.6) | 101 (48.7) | 0.56 |
Medications, n (%) | |||||
 Aspirin | 624 (99.8) | 207 (100.0) | 209 (99.5) | 208 (100) | 0.37 |
 ACEI/ARB | 579 (93.0) | 195 (94.2) | 190 (90.5) | 194 (93.3) | 0.32 |
 β-Blocker | 554 (88.6) | 189 (91.3) | 182 (86.7) | 183 (88.0) | 0.36 |
 Clopidogrel | 610 (97.6) | 204 (98.6) | 203 (97.1) | 203 (97.6) | 0.45 |
 Diuretics | 271 (43.4) | 98 (47.3) | 94 (44.8) | 79 (38.0) | 0.14 |
 Calcium channel blocker | 114 (18.2) | 44 (21.3) | 41 (19.5) | 29 (13.9) | 0.13 |
 Statin | 623 (99.7) | 206 (99.5) | 209 (99.5) | 208 (100) | 0.61 |
 Nitrate | 559 (89.4) | 191 (92.3) | 183 (87.1) | 185 (88.9) | 0.22 |
 Total cholesterol (mmol/L) | 4.10 ± 1.04 | 4.03 ± 1.01 | 4.00 ± 1.00 | 4.27 ± 1.08 | 0.02 |
 Triglyceride (mmol/L) | 1.57 ± 0.85 | 1.54 ± 0.81 | 1.53 ± 0.80 | 1.64 ± 0.93 | 0.34 |
 HDL cholesterol (mmol/L) | 1.04 ± 0.29 | 1.02 ± 0.29 | 1.01 ± 0.25 | 1.10 ± 0.31 | <0.01 |
 LDL cholesterol (mmol/L) | 2.53 ± 0.89 | 2.47 ± 0.89 | 2.46 ± 0.85 | 2.64 ± 0.90 | 0.08 |
 FPG (mmol/L) | 6.06 (5.04–7.79) | 6.02 (5.07–8.05) | 5.99 (5.01–8.15) | 6.19 (5.03–7.78) | 0.88 |
 CK-MB (ng/mL) | 6.42 (1.82–126.10) | 4.73 (1.81–70.05) | 4.71 (1.75–139.20) | 12.01 (1.89–202.45) | 0.05 |
 cTNT (ng/mL) | 0.65 (0.05–4.13) | 0.56 (0.05–3.00) | 0.54 (0.04–4.16) | 1.03 (0.04–5.21) | 0.38 |
 Myoglobin (ng/mL) | 45.80 (28.47–340.30) | 42.89 (28.45–191.68) | 39.95 (27.44–303.43) | 85.30 (28.58–758.50) | 0.03 |
 NT-proBNP (pg/mL) | 974 (342–2234) | 990 (290–2608) | 1139 (383–2241) | 773 (337–1921) | 0.30 |
 Creatinine (umol/L) | 78.50 (68.40–90.40) | 79.00 (65.20–91.90) | 79.90 (70.15–93.45) | 77.30 (68.70–87.20) | 0.19 |
 GGT (U/L) | 32.60 (21.65–54.15) | 30.40 (21.20–47.25) | 30.40 (21.50–51.50) | 37.90 (23.60–72.30) | <0.01 |
 ALT (U/L) | 34.00 (21.10–55.00) | 30.40 (19.20–45.30) | 30.60 (20.70–54.40) | 42.45 (25.45–67.93) | <0.01 |
 AST (U/L) | 29.20 (18.80–65.60) | 26.65 (17.65–51.98) | 29.80 (19.00–68.00) | 32.65 (20.55–84.63) | <0.01 |
Follow-up events, n (%) | |||||
 MACCE | 47 (7.5) | 17 (8.2) | 15 (7.1) | 15 (7.2) | 0.90 |
 CV mortality | 24 (3.8) | 9 (4.3) | 8 (3.8) | 7 (3.4) | 0.87 |
 Non-CV mortality | 9 (1.4) | 1 (0.5) | 2 (1.0) | 6 (2.9) | 0.09 |
 Non-fetal MI | 9 (1.4) | 3 (1.4) | 2 (1.0) | 4 (1.9) | 0.71 |
 HF readmission | 12 (1.9) | 2 (1.0) | 5 (2.4) | 5 (2.4) | 0.47 |
 Stroke | 8 (1.3) | 3 (1.4) | 3 (1.4) | 2 (1.0) | 0.88 |
 Repeated revascularization | 41 (6.6) | 13 (6.3) | 10 (4.8) | 18 (8.7) | 0.27 |